Get to Know Dr. Bruno R. Bastos
Bastos joined the Miami Cancer Institute at Baptist Health South Florida in 2019 after serving at Cleveland Clinical Florida in nearby Weston.
He is a part of a multidisciplinary team that treats kidney, prostate, bladder, urethra, ureter, mesothelioma and several other cancers.
The Miami Cancer Institute is part of the well-respected Memorial Sloan Kettering Cancer Alliance.
Bastos has extensive experience with clinical trials and is board certified in medical oncology, medical hematology and internal medicine.
He is best known for advancing targeted and hormone therapies, particularly immunotherapy, both in the adjuvant and metastatic settings.
“Immunotherapy is a more natural way of treating cancer, rather than attacking the cancer cells with chemicals,” Bastos said. “Immunotherapy allows the patient’s own immune system to do the job it is supposed to do, which is fight the cancer.”
In 2021, Bastos presented his latest research at the American Society of Clinical Oncology’s Annual Meeting. His work focused on a glycogen synthase kinase 3 beta inhibitor in patients with hematologic malignancies or solid tumors.
Specialties of Dr. Bruno Bastos
- Genitourinary cancers
- Peritoneal mesothelioma
- Hormone therapy
- Developmental therapeutics
Dr. Bruno Bastos’ Experience and Medical Education
- Miami Cancer Institute
- Cleveland Clinical Florida
- Dana-Farber Cancer Institute (Fellowship)
- University of Miami School of Medicine (Fellowship)
- Jackson Memorial Hospital (Residency)
- Universidade Federal da Bahia, Brazil (M.D.)
Awards and Certifications
- Board certified in internal medicine, hematology and medical oncology
- Florida Center for Brain Tumor Research Scientific Advisory Council
- Outstanding Patient Experience Award
- Healthgrades Honor Roll
Publications of Dr. Bruno Bastos
- Flaig, T. et al. (2021, March 12). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research.
- Bao, R. et al. (2020, November) Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Research.
- Sadler, D. et al. (2020, July 16). Practical and cost-effective model to build and sustain a cardio-oncology program. Cardio-Oncology.
- Gainor, J.F. et al. (2020, May 25). Nivolumab plus ipilimumab with two cycles of chemotherapy in first-line metastatic non-small cell lung cancer: CheckMate 568 Part 2. Journal of Clinical Oncology.
Thank you for your feedback. Would you like to speak with a Patient Advocate?